Abstract: The present invention refers to steroidal nitrone (E)-N-((8S,9S,10R,13R,14S,17R)-10,13-di methyl-17-(R)-6-methyl hepta n-2-yl)-7,8,9,11,12,13,14,15,16,17-deca hydro-1H-cyclopenta[a]phenanthren-3(2H,6H,10H)-ylidene)methanamine oxide (F2), as well as any pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of permanent cerebral ischemia.

Abstract: The present invention refers to a method directed to RT-qPCR reactions, preferably performed in a one or two-step approach combining the reverse transcription and subsequent PCR in a single tube and buffer, using a reverse transcriptase along with a DNA polymerase with mandatory 3??5? exonuclease activity, which corrects miss-incorporated nucleotides. In particular, in this invention we present a One-step RT-PCR, preferably qPCR, method with a novel priming strategy that utilizes a novel bivalent reverse primer, wherein this primer is used for both, i) the generation of cDNA and ii) the completion of the subsequent amplification using that same cDNA as template. This bivalent reverse primer also allows end-tagging the amplicon(s) obtained so that they can be used in a variety of applications including, standard sequencing, next generation sequencing (NGS), gene expression analysis, RNAi validation, microarray validation, pathogen detection, genetic testing, and disease research.

Abstract: The invention relates to neuroprotective, antioxidant quinolylnitrones to which the blood-brain barrier is highly permeable, as potential drugs for the treatment of a cerebral stroke or ischaemia, Alzheimer's and Parkinson's disease and amyotrophic lateral sclerosis.

Abstract: The present invention is generally directed to methods for detecting and/or quantifying miRNA, RNA or DNA molecules of interest in at least one isolated biological sample. Basically the general procedure followed by the methods of the present invention involve four main steps: (i) homogeneous hybridization of the synthetic DNA or RNA probe and the target miRNA, RNA or DNA molecule of interest; (ii) capture of the resultant DNA/RNA, DNA/DNA or RNA/RNA duplex by the antibody-modified magnetic particles, preferably MBs, in solution; (iii) enzymatic labeling of the biotinylated DNA/RNA, DNA/DNA or RNA/RNA duplex captured onto the antibody-modified magnetic particles, preferably MBs and (iv) electrochemical detection of the modified-magnetic particles on an electrochemical sensor, preferably on screen-printed carbon electrodes (SPCEs).